COPD Therapeutics in Major Developed Markets to 2021 - Emergence of
Addition-in-Class and First-in-Class Products Offsets Sales Erosion of
Leading Brands
Summary
Chronic Obstructive Pulmonary Disease (COPD) is a progressive
disorder associated with chronic inflammation of the airways and lungs.
Persistent breathing difficulties and repeated exacerbations of COPD
symptoms make the disease one of the leading causes of morbidity, and
the fifth-leading cause of death in the world.
Browse Detail Report With TOC @
COPD is linked to cumulative exposure to risk factors, primarily
tobacco smoke, but also environmental pollutants. The COPD marketed
products landscape consists of pharmacological therapies aimed at
managing the symptoms associated with COPD, although none of the
available therapies have been shown to modify long-term disease
progression.
There are currently 203 products in active development, excluding
four with an unknown stage of development. Although many of the targets
identified in the pipeline are well established in the management of
COPD, there are some novel, first-in-class targets. This reflects the
growing understanding of the underlying mechanisms that characterize the
disease.
Scope
The COPD market has benefited from notable additions over recent years.
- Which classes of drug dominate the market?
- What additional benefits have newly approved therapies brought to market?
- How do the leading marketed therapies compare clinically?
- Which molecular targets appear most frequently in the pipeline?
- How will the new therapies be positioned in the treatment of COPD?
- How have selected late-stage pipeline therapies performed in clinical trials?
- What are the failure rates for individual Phases of clinical development?
Reasons to buy
This report will allow you to – - Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in COPD.
- Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies, and a heatmap directly comparing safety and efficacy data.
- Analyze the COPD pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
- Predict growth in market size in eight major markets, with in-depth market forecasting from 2014 to 2021. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.
Hexa Reports is a market research and consulting organization,
offering industry reports, custom research and consulting services to a
host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients
obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Website: http://www.hexareports.com/
Visit our Blog: http://hexareports.blogspot.com/
No comments:
Post a Comment